KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Invested Capital (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Invested Capital for 8 consecutive years, with $480.9 million as the latest value for Q4 2025.

  • Quarterly Invested Capital rose 3.24% to $480.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $480.9 million through Dec 2025, up 3.24% year-over-year, with the annual reading at $480.9 million for FY2025, 3.24% up from the prior year.
  • Invested Capital hit $480.9 million in Q4 2025 for Castle Biosciences, up from $477.1 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $480.9 million in Q4 2025 to a low of $378.8 million in Q2 2023.
  • Historically, Invested Capital has averaged $424.3 million across 5 years, with a median of $417.1 million in 2021.
  • Biggest five-year swings in Invested Capital: soared 269.53% in 2021 and later fell 10.17% in 2023.
  • Year by year, Invested Capital stood at $411.7 million in 2021, then dropped by 3.06% to $399.2 million in 2022, then decreased by 1.97% to $391.3 million in 2023, then grew by 19.06% to $465.9 million in 2024, then increased by 3.24% to $480.9 million in 2025.
  • Business Quant data shows Invested Capital for CSTL at $480.9 million in Q4 2025, $477.1 million in Q3 2025, and $465.4 million in Q2 2025.